Other News

Agilent Presents Thought Leader Award to Professor Jason Kovacic

Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced that Professor Jason Kovacic has been selected to receive a prestigious Agilent Thought Leader Award. Professor Kovacic is being recognized for his influential research on cardiovascular disease—specifically the […]

Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study

DANVERS, Mass.–(BUSINESS WIRE)–Regulators in three countries have granted approvals to Impella surgical products, as Abiomed (NASDAQ: ABMD) continues to execute its strategy for sustainable growth with new products, new indications and new geographies. In the United States, the Food and Drug Administration (FDA) has granted an Early Feasibility Study (EFS) Investigational Device […]

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2021, Provides Financial Outlook for 2022

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, announced preliminary financial results for the fourth quarter and full year 2021 and provided 2022 financial guidance. Preliminary, unaudited revenue for fourth quarter 2021 […]

Medtronic to Acquire Affera

Acquisition to expand company’s cardiac ablation portfolio, including first-time entry into mapping and navigation, within one of the fastest growing medtech markets DUBLIN, Jan. 10, 2022 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it has entered into a definitive agreement to acquire Affera, Inc., […]

Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the United States

Evkeeza is a first-in-class medicine approved by the U.S. Food and Drug Administration (FDA) and European Commission (EC) to treat an ultra-rare inherited form of high cholesterol TARRYTOWN, N.Y. and NOVATO, Calif., Jan. 7, 2022 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Ultragenyx Pharmaceutical Inc. today announced a license and collaboration agreement for Ultragenyx to […]

NICE recommends first smartphone-based ECG for the detection of atrial fibrillation (AF) for people with suspected paroxysmal AF in an ambulatory monitoring setting

AliveCor’s KardiaMobile® is the only personal electrocardiogram (ECG) to be recommended by the National Institute for Health and Care Excellence (NICE) for use within the NHS[1] NICE’s positive recommendation[1] offers patients and physicians across England and Wales access to a medical-grade ECG to support at home monitoring of paroxysmal atrial fibrillation (AF) without the requirements […]

SERIAL INNOVATOR, EITAN KONSTANTINO JOINS GENESIS MEDTECH AS CTO OF VASCULAR INTERVENTIONS FRANCHISE

SINGAPORE, Jan. 7, 2022 /PRNewswire/ — Genesis MedTech Group (Genesis or Group) has appointed Dr. Eitan Konstantino (Eitan) as CTO of Vascular Interventions to propel Genesis’ technology innovation within the neurovascular, cardiovascular and peripheral vascular spaces. His role will include developing and implementing the Group’s global Vascular Interventions R&D strategy, driving the enhancement of […]

Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million

Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten Royalty Pharma Purchases Royalties on Future Sales of Aficamten Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif. and NEW YORK, Jan. […]

AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revises Gross Margin and Adjusted EPS Guidance

Fiscal 2022 Second Quarter Highlights Net sales of $78.3 million increased 7.6% compared to the prior-year quarter Med Tech growth of 36.4% and Med Device growth of 0.8% year over year Gross margin of 51.8% declined 340 basis points year over year GAAP loss per share of $0.21, and adjusted […]